Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. reported results from its 2026 annual stockholder meeting and changes to its equity incentive plan. Stockholders approved an amended and restated 2021 Equity Incentive Plan that keeps the automatic annual share increase but now bases it on both issued and outstanding common shares and shares issuable from pre-funded warrants. The amended plan also provides that, unless an award agreement states otherwise, unvested time-based awards held by an employee will fully vest if the employee’s service ends due to death. Two Class II directors, Andrew Levin and Fouad Namouni, were re-elected, the equity plan amendment was approved, and Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026.
Vor Bio reported that its partner RemeGen has received decisions from China’s National Medicinal Products Administration for telitacicept in two autoimmune kidney and rheumatologic diseases. Telitacicept gained conditional approval for treating adult patients with IgA nephropathy and full approval for adult patients with Sjögren’s disease in China.
The IgA nephropathy decision is based on Phase 2 and Phase 3 data, including a 59% reduction in urinary protein-to-creatinine ratio at Week 39 with telitacicept 240 mg and a favorable safety profile. Telitacicept is described as the first and only BAFF/APRIL-targeting therapy approved for IgA nephropathy.
For Sjögren’s disease, a Phase 3 study showed statistically significant improvements in the ESSDAI disease activity score and clinically meaningful gains in the ESSPRI patient-reported index across 160 mg and 80 mg doses with sustained benefit to Week 48. Telitacicept is the first approved therapy for Sjögren’s disease in China. RemeGen controls development and commercialization in China, while Vor Bio holds exclusive rights outside Greater China and is advancing global Phase 3 programs.
VOR BIOPHARMA INC. reports an amended group Schedule 13G/A disclosing beneficial ownership positions held by several Venrock-related entities and named individuals as of March 31, 2026.
The filing states the Reporting Persons collectively hold positions capped at 5,083,877 shares each under a 9.99% beneficial ownership blocker tied to Pre-Funded Warrants. The company had 48,847,504 shares outstanding as of March 23, 2026 and 2,042,158 shares issuable on the Pre-Funded Warrants — figures used to calculate the reported 9.99% ownership percentages.
VOR Biopharma ownership filing: Verve Capital Limited reports beneficial ownership of 4,999,272 shares of common stock, representing 9.3% of the class as of March 31, 2026. The filing notes pre-funded warrants exercisable for 269,912 shares and bases its percentage on 48,847,504 shares outstanding as of March 23, 2026, adjusted for 4,729,360 shares issued upon exercise of pre-funded warrants on March 23, 2026.
Vor Biopharma reports first-quarter 2026 results showing it remains a clinical-stage company investing heavily in autoimmune programs while holding a large cash balance. The company recorded a net loss of $219.6 million for the three months ended March 31, 2026, largely driven by a $188.4 million non‑cash loss from the change in fair value of warrant liabilities.
Operating expenses were $35.2 million, with research and development at $17.6 million as spending shifted from legacy oncology programs to new telitacicept trials in generalized myasthenia gravis and Sjögren’s disease. General and administrative costs rose to $17.6 million, mainly from higher stock‑based compensation and commercial planning.
Vor reported cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026 and expects this to fund operations into early 2029. The company also highlighted multiple equity financings and warrant structures, including liability‑classified 2025 warrants with a fair value of $638.5 million, as key elements of its capital structure.
VOR BioPharma reports amended ownership disclosures by Qiming-related entities. The filing shows Qiming Venture Partners VIII-HC, L.P. beneficially owns 1,089,767 shares (2.0%), and Qiming Venture Partners VIII Investments, LLC beneficially owns 910,172 shares (1.7%). The filing cites 54,185,582 shares outstanding as of March 31, 2026 for percentage calculations.
The cover pages and incorporated items specify voting and dispositive power figures for each reporting person and include a joint filing agreement incorporated by reference.
VOR Biopharma Inc. amendment to a Schedule 13G/A reports that FMR LLC beneficially owns 1,539,670 shares of common stock, representing 3.2% of the class. The filing states FMR LLC has sole dispositive power over 1,539,670 shares and discloses related signature and exhibit references.
Vor Biopharma Inc. files a preliminary shelf prospectus to register for resale up to 5,338,078 shares of its common stock held by investors from a March 30, 2026 private placement. The shares were issued at $14.05 per share; Vor will receive no proceeds from resales. The registration satisfies contractual registration rights and the company agreed to use reasonable best efforts to have the registration declared effective.